Novo Nordisk (NVO)
is a company for the record books and MBA lesson plans. This Danish
biopharmaceueticals company doesn't try to do very many things, but it
does them very, very well. With modest near-term competitive risks and
substantial potential value in the pipeline, operationally there is
little to fear at Novo Nordisk. The question for investors, as is so
often the case with this stock, is what is the proper price to pay for
that excellence.
Please click here to continue:
Can Anything Stop Novo Nordisk?
No comments:
Post a Comment